Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01932242 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers
A Phase 1 study, sponsored by Elusys Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT01932242 is a Phase 1 study that has completed, run by Elusys Therapeutics. The registered enrollment target is 70 participants.
The verdict
NCT01932242, a Phase 1 study, has completed, sponsored by Elusys Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
To evaluate the safety, tolerability, pharmacokinetics and immunogenicity of repeat administration (two doses) of intravenous (IV) ETI-204.
Interventions
- OTHER Placebo
- BIOLOGICAL ETI-204
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2013-07-23 |
| Est. Completion | 2014-04-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01932242
The ClinicalTrials.gov registry entry for NCT01932242 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Elusys Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01932242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01932242 about?
NCT01932242 is a clinical study titled "Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers". To evaluate the safety, tolerability, pharmacokinetics and immunogenicity of repeat administration (two doses) of intravenous (IV) ETI-204.
What is the current status of trial NCT01932242?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2013-07-23. Estimated completion is 2014-04-19.
What interventions are being tested in trial NCT01932242?
The interventions under investigation include: Placebo (OTHER), ETI-204 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01932242?
This trial is sponsored by Elusys Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.